News Releases

News Releases

Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Nov 09, 2022
- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision program PRA052 - - Strong cash position provides runway into mid-2024 - SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc.

Prometheus Biosciences to Participate at November Healthcare Conferences

Nov 01, 2022
SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment

Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052

Oct 03, 2022
- PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF - - PRA052 is the second clinical candidate identified using the Prometheus360™ platform with one of the strongest genetic

Prometheus Biosciences to Participate at September Healthcare Conferences

Aug 31, 2022
SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment

Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Aug 11, 2022
- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022  - - Bioavailability greater than 80% achieved upon completion of PRA023 subcutaneous bridging study - - Unveiled Prometheus’ second precision candidate, PRA052, a first-in-class monoclonal

Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022

Jul 18, 2022
- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 - - PRA052 is a novel, first-in-class monoclonal antibody addressing a target with one of the strongest genetic

Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis

Jul 18, 2022
- Global Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies - - Enrollment initiated in Cohort 2 of CDx+ patients to evaluate the company’s companion diagnostic - -  Both APOLLO-CD and ARTEMIS-UC topline results on track for

Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies

Jun 08, 2022
- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn’s disease patients - - ARTEMIS-UC Phase 2 Cohort 1 enrollment on track with completion expected 3Q 2022 - - Both APOLLO-CD and ARTEMIS-UC topline results expected 4Q 2022 – SAN DIEGO, June 08, 2022 (GLOBE

Prometheus Biosciences to Participate at the Jefferies Healthcare Conference

May 26, 2022
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of

Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

May 12, 2022
- Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - - Announced key appointments in Leadership Team - - Strong cash position of $227 million as of March 31, 2022 -
Displaying 11 - 20 of 53